# Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)

> **NCT00475098** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 553 (actual)

## Conditions studied

- Lung Cancer
- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Tinzaparin sodium 100 UI/Kg/OD for 12 weeks

## Key facts

- **NCT ID:** NCT00475098
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 553 (ACTUAL)
- **Last updated:** 2016-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00475098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00475098, "Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00475098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*